1Polish Transplant Coordinating Centre Poltransplant
2Department of Transplantation and General Surgery, Antoni Jurasz University Hospital No. 1 in Bydgoszcz, Poland
3Department of Vascular Surgery, Transplantation and Liver Surgery Clinical Department of Transplantation Surgery and Liver Surgery, 4th Military Clinical Hospital SP ZOZ in WrocÅaw, Poland
4Department of General, Transplant and Liver Surgery, University Clinical Center of the Medical University of Warsaw, Poland
5Department of Urology, Collegium Medicum, University of Zielona Góra, Poland
6Department of Pediatric Surgery and Organ Transplantation, The Children’s Memorial Health Institute in Warsaw, Poland
7Department of General and Transplant Surgery, University Clinical Center of the Medical University of Warsaw - Infant Jesus Clinical Hospital, Poland
8Department of General, Vascular and Transplant Surgery, Independent Public Clinical Hospital named after Andrzej MielÄcki, Medical University of Silesia in Katowice, Poland
9Department of Vascular, General and Transplantation Surgery, University Clinical Hospital, WrocÅaw Medical University, Poland
10Department of Oncological, Transplantation and General Surgery, University Clinical Centre in GdaÅsk, Poland
11Department of General, Liver and Transplant Surgery Antoni Jurasz University Hospital No. 1
in Bydgoszcz, Collegium Medicum, Nicolaus Copernicus University in ToruÅ, Poland
12Department of General and Transplant Surgery with Subdivision of Oncological Surgery, Department of Vascular Surgery, Independent Public Regional Hospital in Szczecin, Poland
13Department of Biochemistry and Microbiology, Warsaw University of Life Sciences, Poland
14Department of Transplantology and Central Tissue Bank, Medical University of Warsaw, Poland
15Department of Emergency Medicine, Medical University of Warsaw, Poland
Aleksandra Woderska-JasiÅska*
Aleksandra Woderska-JasiÅska, et.al., (2025). Impact of COVID-19 Pandemic on Numbers and Characteristics of Liver Transplantations. Transplantation Proceedings and Research. 4(1); DOI: 10.58489/2836-8991/008
© 2025 Aleksandra Woderska-JasiÅska, this is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
liver transplantation, COVID-19, registries
The purpose of the study is to provide a comprehensive overview of the liver donation and transplantation activity in Poland highlighting the impact of COVID-19 pandemic.
Reported data is based on the national transplant registries maintained by Polish Transplant Coordinating Centre Poltransplant: the national waiting list (indications) and transplantation registry (numbers of transplantations and results). This review compares the activity, characteristics of recipients and early (3-month) results of liver transplants from deceased and living donors during COVID-19 era (2020-2021) to the pre-pandemic periods (2018-2019 and 2012-2017, 2001-2011) and the long-term period (2001-2021).
In the COVID-19 era the number of hepatic transplants from deceased donors distinctly decreased (12%), but the number of transplanted livers to pediatric recipients that remained stable. The indications for the liver transplantation (LT) have not changed significantly, except the incidence of liver cirrhosis as an indication for the primary LT in pediatric recipients and the incidence of primary non-function (PNF) as an indication for the reLT in adult recipients. In COVID-19 era the retransplantation status has also changed. The number of urgent cases decreased. Early liver transplant results have not changed.
This overview indicates that the COVID-19 pandemic affected liver transplant programs in Poland. The number of liver transplantations from deceased donors in adult and pediatric recipients decreased. The total number of liver transplantations to pediatric recipients was stable. Early liver transplantation results have not changed and the indications for liver transplantation remained largely the same as in previous years.
Liver transplantation (LT) is a life-saving procedure for patients with acute and chronic liver failure. More than 200000 liver transplants were already performed worldwide. According to Global Report (https://www.transplant-observatory.org/2021-global-report-5/ accessed on 30.12.2023), only in 2021, 34 694 liver grafts were transplantated in 68 countries.
In Poland, between 1987 and 2024, 6614 liver transplants were performed: 6128 from deceased donors (DD), 486 from living donors (LD) and 80 livers were transplanted simultaneously with kidney, 7 with heart, 1 with lung and 1 with pancreas (https://files.poltransplant.org.pl/Biuletyn_2024_www.pdf?utm_source=Poltransplant&utm_medium=biuletyn&utm_campaign=Biuletyn+Informacyjny+Poltransplantu+2024 accessed on 22.12.2024). Simultaneous liver-kidney transplants have been performed in Poland for 24 years (since 2000), however the first simultaneous liver-pancreas transplantation was performed during the COVID-19 pandemic (in 2021). The paper provides a comprehensive overview of the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 pandemic on adult and pediatric liver transplantation programs in Poland.
According to the International Registry in Organ Donation and Transplantation (IRO-DaT, https://www.irodat.org accessed on 30.12.2023) in 2021 in Poland with the number of 273 liver transplants, which was the lowest in the last decade, the rate of liver transplantation from deceased donors was 7.4 pmp, that statistically ranked Poland on 28th place out of 62 countries (max. USA - 26.18 pmp, min. Dominican Republic - 0.1 pmp). The rate 0.52 pmp from living donors (n=20) ranked Poland on 30th out of 50 countries (max. South Korea - 22.42 pmp, min. Spain - 0.02 pmp). However, according to the national transplant registries, in the next year the number of hepatic transplants from deceased donors in Poland increased by 20%, so the rate of total liver transplants increased from 7.86 pmp in 2021 to 9.6 pmp in 2022. According to Global Report (https://www.transplant-observatory.org/summary/ accessed on 30.12.2023), in 2022 the European rate was 14.22 pmp and global rate was 6.28 pmp. It is worth to emphasize, that in 2023 in Poland the total number of liver transplants increased to 523, and further increased in 2024, reaching the highest historical level – 562 (http://www.poltransplant.org.pl/statystyka_2024.html#gsc.tab=0 accessed on 22.12.2024).
Comparative analysis of retrospective data regarding liver donation from deceased and living donors as well as liver transplantation to adult and pediatric recipients is based on the national transplant registries maintained by the Polish Transplant Coordinating Centre Poltransplant: the national waiting list (indications) and transplant register (numbers of liver retrieval and transplantation procedures and its results). Gathered data are presented in tables according to selected variables that are significant empirical indicators of the efficiency of transplant programs and provide essential information for national and international benchmarking.
This review compares the activity (average annual number of transplantations), characteristics of recipients (according to indications for transplantation) and early (3-month) results of liver transplants from deceased and living donors. The calculated and analyzed indicators are given as follows: during the pre-pandemic two-year period (2018-2019), in the COVID-19 pandemic two-year period (2020-2021) and in the long-term period (2001- 2021). However, in order to present the broader overview and possible trends, additional pre-pandemic periods: 2001-2011 and 2012-2017 are also provided.
General data on liver donation and transplantation in Poland
Liver donors and recipients
The total number of liver transplants in Poland during the COVID-19 pandemic (2020-2021) was 588. It was a 12% decrease comparing to the activity (668 transplants) in the two years before the pandemic (2018-2019), but still more than in the long-term period (average 266 transplantations per year in years 2001-2021). The decrease in the number of transplants affected adult recipients (520 vs. 603 transplants) and was due to the lower number of utilised deceased donors of this organ. However, the number of transplants in children, despite a 9% decrease of deceased donors rate, remained at similar level (68 vs. 65), which was due to the 12% increase in the activity of living donor liver transplantation (LDLT) program (48 vs. 43).
Primary liver transplantation and liver retransplantation
During pandemic, liver retransplantation (reLT) amounted 6% of all 588 LT procedures performed. This rate was the lowest comparing to the pre-pandemic period (8%) and long-term period 2001-2021 (7%) (Table 1).
In most cases (57) of the liver retransplantation in pediatric recipients (64 reLT in 21 years), liver grafts were retrieved from deceased donors. During pandemic there were one reLT performed in pediatric recipient, but the liver was harvested from a living donor.
Detailed data and indications for reLT in adult and pediatric recipients are presented in further sections of the paper.
Early liver transplantation results
The early (3-month survival rate of recipients with functioning transplants) results of liver transplantation according to the type of donors (deceased, living), the age of the recipients (adult, pediatric) and type of LT (primary or reLT) are presented in (Table 2). The best transplantation results were achieved in the following profiles:
Adult recipients
Numbers and characteristics of primary liver transplantation
The indications for first-time elective liver transplantation in adult recipients did not change substantially during the pandemic period (Table 3). Cirrhosis of various etiologies was the most frequent indication (64%), as in the log-term period (66%). The changes in ethiology of cirrhosis are presented in (Table 4). In the long-term period alcoholic liver disease (ALD) and hepatitis C virus have been most common etiologies of the liver cirrhosis (26% and 22%, respectively). Nevertheless, during the pandemic the rate of alcoholic liver cirrhosis has increased (42%).
In all analyzed periods: the pre-pandemic, the pandemic and the long-term period 2001 - 2021, 15% of all indications for first-time liver transplantation in adult recipients were hepatocellular carcinoma (HCC) (Table 5). In the COVID-19 era, however, for the first time since 2001, an increase in the number of primary transplants for HCC developed in non-cirrhotic livers and a decrease in the number of transplants due to HCC located in the cirrhotic liver were observed. Other than HCC, primary or secondary liver cancers, both in the pandemic period and the long-term period, accounted for 9% of the performed transplants in the group of cancer indications and 2% of all indications.
During the pandemic period an acute liver failure of various etiologies was a less frequent (3%) indication for primary liver transplantation in adult recipients comparing to pre-pandemic period (5%) and the long-term period (4%) (Table 6).
The predominant indications were paracetamol or other drugs overdose and unrecognised causes (31%) as well as liver injuries (19%).
Numbers and characteristics of liver re-transplantation
In pandemic period most (57%) of the reLT procedures were performed in patients awaiting elective liver transplantation. The number of liver retransplantations in urgent cases was lower (43%) comparing to pre-pandemic and the long-term periods (59%).
The most common indications for retransplantation during the pandemic period in adult recipients were vascular complications (43%) and recurrence of non-cancerous primary liver disease (23%) (Table 7). The proportion of these indications for retransplantation was most likely similar in the ling-term period 2001-2021, but there is a level of uncertainty, due to the unreported data in the 2001-2017 period. The incidence of primary non-function (PNF) as an indication for the reLT in adult recipients was found as a significant difference (p=0.03).
Pediatric recipients
Numbers and characteristics of primary liver transplantation
The most common indications for elective treatment with primary liver transplantation (whole organ or part of it in the case of living donors) in pediatric recipients during the pandemic period were congenital biliary atresia (51% of all transplants), cirrhosis (13%), primary (non-HCC) liver tumors (10%) and metabolic diseases (9%) (Table 8). These rates over the past 20 years of liver transplantation in children were respectively: atresia - 41%, cirrhosis - 10%, primary (other than HCC) liver tumors - 7% (mainly hepatoblastoma) and metabolic diseases - 11% (most commonly Wilson's disease, alpha-1 – antitrypsin deficiency, cystic fibrosis) (Table 9).
Table 1: Liver retransplantation in adult and pediatric recipients
Donor type |
Recipient |
2001 – 2011 |
2012 – 2017 |
2018 – 2019 |
2020 – 2021 |
2001-2021 |
||||||||||
LT+reLT |
reLT |
% |
LT+reLT |
reLT |
% |
LT+reLT |
reLT |
% |
LT+reLT |
reLT |
% |
LT+reLT |
reLT |
% |
||
Deceased donor |
Adults |
1829 |
85 |
5 |
1857 |
143 |
8 |
603 |
49 |
8 |
520 |
35 |
7 |
4809 |
312 |
6 |
Pediatric |
238 |
41 |
17 |
86 |
13 |
15 |
22 |
3 |
14 |
20 |
0 |
0 |
366 |
57 |
16 |
|
Living donor |
Pediatric |
188 |
2 |
1 |
136 |
3 |
2 |
43 |
1 |
2 |
48 |
1 |
2 |
415 |
7 |
2 |
Total |
2255 |
128 |
6 |
2079 |
159 |
8 |
668 |
53 |
8 |
588 |
36 |
6 |
5590 |
376 |
7 |
Table 2: Early (3-month) results of liver transplantation (LT) according to the type of donors (deceased, living), the age of the recipients (adult, pediatric) and type of transplantation (primary or retransplantation)
|
2001 – 2011 |
2012 – 2017 |
2018 – 2019 |
2020 – 2021 |
2001-2021 |
|||||
Recipients with functioning liver graft/ all LT |
% |
Recipients with functioning liver graft/ all LT |
% |
Recipients with functioning liver graft/ all LT |
% |
Recipients with functioning liver graft/ all LT |
% |
Recipients with functioning liver graft/ all LT |
% |
|
Deceased donors |
||||||||||
All recipients/all LT |
1749/2167 |
81 |
1714/1943 |
88 |
539/625 |
86 |
491/540 |
91 |
4493/5175 |
87 |
Adult recipients/all LT |
1545/1929 |
80 |
1636/1857 |
88 |
519/603 |
86 |
471/520 |
91 |
4171/4808 |
87 |
Adult recipients/ primary LT |
1488/1844 |
81 |
1536/1714 |
90 |
486/554 |
88 |
444/485 |
92 |
3954/4497 |
88 |
Adult recipients/ reLT |
57/85 |
67 |
100/143 |
70 |
33/49 |
67 |
27/35 |
77 |
217/312 |
70 |
Pediatric recipients/all LT |
204/238 |
86 |
78/86 |
91 |
20/22 |
91 |
20/20 |
100 |
322/366 |
88 |
Pediatric recipients/primary LT |
174/197 |
88 |
66/73 |
90 |
17/19 |
89 |
20/20 |
100 |
277/309 |
90 |
Pediatric recpipients/reLT |
30/41 |
73 |
12/13 |
92 |
3/3 |
100 |
– |
– |
45/57 |
79 |
All recipients/primary LT |
1662/2041 |
81 |
1602/1787 |
90 |
503/ 573 |
88 |
464/505 |
92 |
4231/4806 |
88 |
All recipients, reLT |
87/126 |
69 |
112/156 |
72 |
36/52 |
69 |
27/35 |
77 |
262/369 |
71 |
Living donors |
||||||||||
Pediatric recipients/all LT |
169/188 |
90 |
129/136 |
95 |
39/43 |
91 |
42/48 |
88 |
379/415 |
91 |
Pediatric recipients/primary LT |
168/186 |
90 |
126/133 |
95 |
39/42 |
93 |
42/47 |
89 |
375/408 |
92 |
Pediatric recipients/ reLT |
1/2 |
50 |
3/3 |
100 |
0/1 |
– |
0/1 |
– |
4/7 |
57 |
Table 3: Indications for primary liver transplantation in adult recipients
Indication |
2001 – 2011 |
2012 – 2017 |
2018 – 2019 |
2020 – 2021 |
2001 – 2021 |
n (%) |
n (%) |
n (%) |
n (%) |
n (%) |
|
Cirrhosis |
984 (56) |
841 (49) |
276 (50) |
251 (52) |
2352 (52) |
Cholestatic liver diseases |
275 (16) |
233 (14) |
94 (17) |
72 (15) |
674 (15) |
HCC in cirrhotic liver |
79 (5) |
329 (19) |
66 (12) |
50 (10) |
524 (12) |
Metabolic liver diseases |
93 (5) |
49 (3) |
27 (5) |
28 (6) |
197 (4) |
Acute liver failure |
82 (5) |
61 (4) |
25 (5) |
16 (3) |
184 (4) |
HCC* in non-cirrhotic liver |
37 (2) |
40 (2) |
16 (3) |
26 (5) |
119 (3) |
Viral cirrhosis and ALD** |
34 (2) |
51 (3) |
9 (2) |
11 (2) |
105 (2) |
Other or unidentified liver diseases |
60 (3) |
27 (2) |
2 (0.4) |
3 (1) |
92 (2) |
Budd–Chiari Syndrome |
38 (2) |
26 (2) |
7 (1) |
7 (1) |
78 (2) |
Benign liver tumors |
20 (1) |
15 (1) |
14 (3) |
7 (1) |
56 (1) |
Primary liver tumors |
13 (1) |
16 (1) |
7 (1) |
3 (1) |
39 (1) |
Parasitic liver diseases |
15 (1) |
15 (1) |
3 (1) |
5 (1) |
38 (1) |
Secondary liver tumors |
10 (1) |
6 (0) |
4 (1) |
4 (1) |
24 (1) |
Congenital biliary diseases |
4 (0) |
5 (0) |
4 (1) |
2 (0.4) |
15 (0.3) |
Total |
1744 |
1714 |
554 |
485 |
4497 |
Table 4: Etiology of cirrhosis – the most common indication for elective, primary liver transplantations
|
2001 – 2011 |
2012 – 2017 |
2018 – 2019 |
2020 – 2021 |
2001 – 2021 |
|
Indication |
n (%) |
n (%) |
n (%) |
n (%) |
n (%) |
% of liver transplants |
ALD |
258 (24) |
267 (22) |
131 (37) |
130 (42) |
786 (26) |
17 |
HCV* |
351 (32) |
226 (19) |
36 (10) |
31 (10) |
644 (22) |
14 |
HCC in cirrhotic liver |
79 (7) |
329 (27) |
66 (19) |
50 (16) |
524 (18) |
12 |
AIH** |
129 (12) |
127 (10) |
46 (13) |
34 (11) |
346 (12) |
8 |
HBV*** |
118 (11) |
81 (7) |
24 (7) |
22 (7) |
245 (8) |
5 |
Other or unidentified |
87 (8) |
65 (5) |
34 (10) |
26 (8) |
212 (7) |
5 |
HCV/HBV |
41 (4) |
75 (6) |
5 (1) |
8 (3) |
129 (4) |
3 |
Viral liver cirrhosis |
34 (3) |
51 (4) |
9 (3) |
11 (4) |
105 (4) |
2 |
Total |
1097 |
1221 |
351 |
312 |
2981 |
66 |
*HCV - cirrhosis caused by hepatitis C virus
**AIH - Autoimmune hepatitis
***HBV - cirrhosis of the liver caused by the hepatitis B virus
Table 5: Tumor as an indication for liver transplantation in adult recipients
Indication |
2001 – 2011 |
2012 – 2017 |
2018 – 2019 |
2020 – 2021 |
2001 – 2021 |
|
n (%) |
n (%) |
n (%) |
n (%) |
n (%) |
% of LT |
|
HCC in cirrhotic liver |
79 (57) |
329 (86) |
66 (71) |
50 (60) |
524 (74) |
12% |
HCC in non-cirrhotic liver |
37 (27) |
40 (10) |
16 (17) |
26 (31) |
119 (17) |
3% |
Primary liver tumors |
13 (9) |
16 (4) |
7 (8) |
3 (4) |
39 (6) |
1% |
Secondary liver tumors |
10 (7) |
6 (2) |
4 (4) |
4 (5) |
24 (3) |
1% |
Total |
139 |
391 |
93 |
83 |
706 |
17% |
Table 6: Primary liver transplantation in acute liver failure in adult recipients
Indication |
2001 – 2011 |
2012 – 2017 |
2018 – 2019 |
2020 – 2021 |
2001 – 2021 |
n (%) |
n (%) |
n (%) |
n (%) |
n (%) |
|
Other or unidentified |
28 (34) |
18 (30) |
9 (36) |
5 (31) |
60 (33) |
Mushroom (toadstool) poisoning |
23 (28) |
13 (21) |
1 (4) |
1 (6) |
38 (21) |
Paracetamol or other drugs overdose |
9 (11) |
14 (23) |
4 (16) |
5 (31) |
32 (18) |
HBV |
3 (4) |
7 (11) |
3 (12) |
1 (6) |
14 (8) |
AIH |
1 (1) |
4 (7) |
4 (16) |
1 (6) |
10 (5) |
Liver injury |
3 (4) |
3 (5) |
1 (4) |
3 (19) |
10 (5) |
Wilson’s disease |
8 (10) |
1 (2) |
1 (4) |
– |
10 (5) |
HCV |
4 (5) |
– |
2 (8) |
– |
6 (3) |
Budd – Chiari syndrome (BCS) |
1 (1) |
1 (2) |
– |
– |
2 (1) |
HAV* |
1 (1) |
– |
– |
– |
1 (1) |
PSC** |
1 (1) |
– |
– |
– |
1 (1) |
Acute liver failure (total) |
82 |
61 |
25 |
16 |
184 |
*HAV - liver cirrhosis caused by hepatitis A virus infection
**PSC – Primary sclerosing cholangitis
Table 7: Indications for liver retransplantation in adult recipients
Indication |
2001 – 2011 |
2012 – 2017 |
2018 – 2019 |
2020 – 2021 |
2001 – 2021 |
n (%) |
n (%) |
n (%) |
n (%) |
n (%) |
|
No information available; Cause unidentified |
85 (100) |
124 (87) |
5 (10) |
1 (3) |
215 (69) |
Vascular complications |
– |
– |
19 (39) |
15 (43) |
34 (11) |
Relapse of the primary liver disease (neoplasms excluded) |
– |
8 (5) |
6 (12) |
8 (23) |
22 (7) |
Biliary complications |
– |
10 (7) |
5 (10) |
2 (6) |
17 (5) |
Primary nonfunction (PNF) |
– |
–
|
1 (2) |
5 (14)* |
6 (2) |
Septic complications |
– |
1 (<1) |
1 (2) |
2 (6) |
4 (1) |
Chronic graft rejection |
– |
– |
2 (4) |
1 (3) |
3 (10) |
Cancer relapse |
– |
– |
– |
1 (3) |
1 (<1) |
Total |
85 |
143 |
49 |
35 |
312 |
* Significant difference, p=0.03
Table 8: Indications for the primary liver transplantation in pediatric recipients (from deceased and living donors)
Indication |
2001 – 2011 |
2012 – 2017 |
2018 – 2019 |
2020 – 2021 |
2001 – 2021 |
n (%) |
n (%) |
n (%) |
n (%) |
n (%) |
|
Biliary athresia |
140 (37) |
83 (40) |
36 (59) |
34 (51) |
293 (41) |
Other or unidentified |
83 (22) |
13 (6) |
1 (2) |
1 (1) |
98 (14) |
Metabolic diseases |
37 (10) |
35 (17) |
4 (7) |
6 (9) |
82 (11) |
Cirrhosis |
46 (12) |
18 (9) |
2 (3) |
9 (13)* |
75 (10) |
Acute liver failure |
27 (7) |
16 (8) |
5 (8) |
4 (6) |
52 (7) |
Primary liver tumor (excluding HCC) |
16 (4) |
21 (10) |
8 (13) |
7 (10) |
52 (7) |
Cholestatic diseases |
15 (4) |
10 (5) |
4 (7) |
4 (6) |
33 (5) |
HCC in non-cirrhotic liver |
9 (2) |
6 (3) |
0 (0) |
2 (3) |
17 (2) |
Benign liver tumors |
8 (2) |
1 (0) |
1 (2) |
0 (0) |
10 (1) |
Budd– Chiari syndrome (BCS) |
2 (1) |
2 (1) |
0 (0) |
0 (0) |
4 (1) |
Total |
383 |
206 |
61 |
67 |
717 |
Significant difference, p=0.04
Table 9: Metabolic diseases as indications for liver transplantation in pediatric recipients
Indication |
2001 – 2011 |
2012 – 2017 |
2018 – |
2020 – |
2001 – 2021 |
||
n |
n |
n |
n |
n |
% of all LT * |
% of LT due to metabolic diseases ** |
|
Cystic Fibrosis (CF) |
8 |
6 |
1 |
1 |
16 |
2% |
20% |
Wilson’s disease |
10 |
5 |
1 |
– |
16 |
2% |
20% |
Alpha – 1 Antitrypsine Deficiency (AATD) |
7 |
5 |
1 |
2 |
15 |
2% |
18% |
Oxalosis |
5 |
1 |
– |
– |
6 |
1% |
7% |
Maple Syrup Urine Disease (MSD) |
– |
4 |
– |
– |
4 |
1% |
5% |
Hyperammonemia |
1 |
3 |
– |
– |
4 |
1% |
5% |
Ornithine Transcarbamylase Deficiency (OTCD) |
– |
2 |
– |
1 |
3 |
<1% |
4% |
Argininosuccinic Aciduria (AS) |
– |
2 |
– |
– |
2 |
<1% |
2% |
Graft –Versus– Host Disease (GvHD) |
1 |
– |
– |
1 |
2 |
<1% |
2% |
Hemolytic Uremic Syndrome (HUS) |
– |
2 |
– |
– |
2 |
<1% |
2% |
Nonalcoholic Steatohepatitis (NASH) |
1 |
1 |
– |
– |
2 |
<1% |
2% |
Tyrosinemia |
– |
1 |
– |
1 |
2 |
<1% |
2% |
Byler’s disease (Progressive familial intrahepatic cholestasis - PFIC) |
1 |
– |
– |
– |
1 |
<1% |
1% |
Carbamoyl -Phosphate Synthetase 1 Deficiency (CPS1D) |
– |
1 |
– |
– |
1 |
<1% |
1% |
Glikogenosis |
1 |
– |
– |
– |
1 |
<1% |
1% |
Hemochromatosis |
1 |
– |
– |
– |
1 |
<1% |
1% |
Long– Chain 3 Hydroxyacyl-Coenzyme A Dehydrogenase Deficiency (LCHAD) |
1 |
– |
– |
– |
1 |
<1% |
1% |
Glycosylation disorders |
– |
1 |
– |
– |
1 |
<1% |
1% |
Berdon’s syndrome (Megacystis microcolon intestinal hypoperistalsis syndrome – MMIH) |
– |
1 |
– |
– |
1 |
<1% |
1% |
Tricho–hepato–enteric syndrome (THE) |
– |
– |
1 |
– |
1 |
<1% |
1% |
Total |
37 |
35 |
4 |
6 |
82 |
11% |
100% |
* all LT in pediatric recipients - 717
** LT due to metabolic diseases in pediatric recipients - 82
Table 10: Primary liver transplantation in acute organ failure in pediatric recipients
Indication |
2001 – 2011 |
2012 – 2017 |
2018 – 2019 |
2020 – 2021 |
2001 – 2021 |
n (%) |
n (%) |
n (%) |
n (%) |
n (%) |
|
Other or unidentified |
7 (26) |
14 (88) |
3 (60) |
3 (75) |
27 (52) |
Mushroom (toadstool) poisoning |
10 (37) |
2 (13) |
– |
1 (25) |
13 (25) |
Paracetamol overdose (other drugs) |
4 (15) |
– |
– |
– |
4 (8) |
HBV |
3 (11) |
– |
– |
– |
3 (6) |
TALDO syndrome |
– |
– |
2 (40) |
– |
2 (4) |
Wilson’s disease |
1 (4) |
– |
– |
– |
1 (2) |
HAV |
1 (4) |
– |
– |
– |
1 (2) |
Fibrosis |
1 (4) |
– |
– |
– |
1 (2) |
Total acute liver failure |
27 |
16 |
5 |
4 |
52 |
The rate of primary transplants for acute organ failure during the pandemic period for pediatric recipients was 6%, and did not differ markedly from that calculated for the long-term period 2001-2021 (7%). The most common indications were a toadstool poisoning (25%) and unidentified causes (75%) (Table 10).
Numbers and characteristics of liver re-transplantation
Only one retransplant (in the urgent recipient) was performed in pediatric recipient during the pandemic period (2020-2021), and four (two in urgent recipients) in years 2018-2019. During the long-term period 2001-2021, a total of 64 retransplants (average 3.2 per year) were performed in this population of recipients, accounting for 8% of all transplants. As the information on the indications for retransplantation in children in the long-term 2001-2021 period is mostly unreported, thus statistical study in this area is not feasible.
coronavirus infection ("patient zero") was confirmed in Poland. At the end of May 2020, three months of the pandemic, the total number of confirmed cases of COVID-19 infection was 23 786, three months later (end of August) there were 67 372 patients, and after one year (March 4, 2021) the quantity reached 1 750 659 cases. Since the beginning of the pandemic, there have been restrictions on the provision of health services, other than those related to COVID-19,caused directly by the impact of the virus itself (infected medical personnel, patients' fear of moving and undergoing medical procedures in treatment facilities), but primarily due to secondary measures to treat the infected and curb the pandemic (conversion of hospitals into hospitals dedicated to treating COVID-19 patients, limiting elective procedures, committing forces and resources to fight the pandemic, the exodus of personnel to newly established temporary hospitals). All of these phenomena also affected transplant medicine, and the strength of their impact the transplant professionals observed on a daily basis.
A worldwide decrease in transplantation, including LT, was reported during COVID-19 pandemic, particularly in 2020 [1-4]. A decrease was also reported for pediatric LT [5] and living donor LT [6]. The extent of this effect differed from country to country, with some recovering quickly [7].
In Poland during the pandemic era many centers active in organ donation and transplant programs have decreased or even temporarily suspended their activity, becoming a COVID-19 designated hospitals. In Poland, since the pandemic era, the trans-plant programs have been led according to SARS-CoV-2 related recommendations developed by the national medical consultants and national authorities and institutions, as the Ministry of Health and the Polish Transplant Coordinating Centre Poltransplant. The latest update of the recommendations was published December 6, 2023
(https://poltransplant.pl/Download/covid/2023_12_06_Stanowisko_Poltransplantu_ws_COVID-19.pdf).
Due to the decrease of the donation and transplantation rates, numerous patients with organ failures awaiting for transplants became collateral victims of the pandemic. Only in 2021, 34 patients in Poland died while waiting for liver transplants on the national waiting list. According to the national transplant registries, at the end of November 2024, in Poland there were 195 patients still awaiting for liver transplantation (including 1 for simultaneous liver and lung and 4 for simultaneous liver and kidney transplantation), therefore there are complex measures that must to be undertaken to increase availability to this method of treatment. Interestingly, no decrease in the total number of LTs in pediatric recipients was observed in Poland. The decrease of LTs from deceased donors was compensated by the increase of LTs from living donors.
The indications for LT remained largely the same in 2020-2021 as in previous years. This is similar to the results in France reported by Legeai et al [3].
Alcohol-related liver disease (ALD) is one of the most prevalent types of liver disease worldwide [8]. It is also a major indication for liver transplantation worldwide [9]. Alcoholic liver cirrhosis represents the second most frequent indication for liver trans-plantation worldwide, accounting for about 30% of all primary transplants in Europe and about 25% in the USA [8]. Interestingly, some studies reported an increase in harmful alcohol use and ALD in years 2020-2021 [10-13]. An increase in the incidence of ALD before and during the pandemic was observed in the United States [14]. In Poland, ALD is a predominant indication for LT with frequency increasing over the years, including the 2020-2021 period.
No significant differences were observed in the indications for liver transplantation in adult recipients during the pandemic period compared to the previous two years. Even those visible in Table 8 (paracetamol and other drugs overdose (31%) and liver injury (19%) in acute liver failure) are not statistically significant (p=0.25 and p=0.11, respectively). The only two statistical significant differences between pandemic (2020-2021) and pre-pandemic period (2018-2019) were the increased incidence of liver cirrhosis as an indication for the primary LT in pediatric recipients (p=0.04) and increased incidence of primary non-function (PNF) as an indication for the reLT in adult recipients (p=0.03).
Moreover, it is worth noting that over the years the number of unidentified diseases as indication for reLT in adult recipients has been decreasing over the years, probably due to improved data reporting to transplant registries.
After the decrease in LTs in years 2020-2021, an increase was observed in Poland, with 334 LTs performed in 2022, 523 in 2023 and 562 in 2024 (at the end of November 2024). This is in line with a post-pandemic increase in transplantation activity observed in other countries.
In the era of COVID-19 in Poland: